Search Results

Refine Search

News & Features

How post-filing data rescued Novo Nordisk’s Ozempic patent in China

The Beijing IP court’s decision to revive a key semaglutide patent based on experimental data has far-reaching legal and economic implications, says Jennifer Che of Eagle IP 15 October 2024

Asia

How to navigate patent term adjustment in China

Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP. 8 October 2024

Americas

‘Masking only works for so long’: Working with ADHD

Being a lawyer with ADHD is far from easy due to widespread misconceptions about the condition but there are ways to offer support, says Lisa Mueller of Casimir Jones. 1 August 2024

Big Pharma

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details. 19 March 2024

Careers

Fenwick establishes new Boston office with trio of IP partners from Cooley

Firm’s chair says Fenwick has been active in market for a long time and “waiting to find the right opportunity to deepen our bench and presence”. 17 April 2025

Americas

How pharma should prep for the six-bill avalanche from Congress

The bipartisan legislative push could create big hurdles for drug development, with concerns mounting over limited patent protections and increased litigation risks, hears Marisa Woutersen. 17 April 2025

Big Pharma

AstraZeneca unit faces class-action suit over alleged Soliris monopoly

Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion. 17 April 2025

Americas

USPTO speeds up patent issuance amid widespread agency changes

Prompter patent issue will provide earlier protection for inventions and could avoid need for Quick Path Information Disclosure Statements, says USPTO. 17 April 2025

Careers

Lathrop GPM adds portfolio management specialist

New partner brings 16 years of experience in biotechnology and pharmaceutical patent prosecution to Chicago | Regularly advises on animal biotechnology, antibodies and biologics, cell biology, chemical technologies, medical devices, and vaccines. 16 April 2025

Big Pharma

Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug

Court hears arguments from J&J and Teva to determine whether a patent blocking generic versions of Invega Sustenna will be upheld | J&J fights to protect its last remaining Orange Book patent covering Invega Sustenna. 15 April 2025